Approval · Notice of Compliance 10994 · 2010
CERVARIX: Notice of Compliance 10994
Issued February 3, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10994
- Date
- February 3, 2010
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Active immunizing agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CERVARIX | 02342227 | Marketed |
Medicinal ingredients
- RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN 20 MCG per 0.5ML
- RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN 20 MCG per 0.5ML